Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisolone added to risperidone for children with autism spectrum disorder
IRCT20090117001556N102Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Dec 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Autism Spectrum Disorder (ASD) comparing Prednisolone + risperidone with Risperidone control (2 arms). Primary endpoint: Severity of autism. Started Dec 2017; status: completed.
02
Drugs
prednisolonerisperidone
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20090117001556N102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N102.